Indaptus Therapeutics is trading 12.74% up at $3.54 as investors continue responding to its September 10 announcement of an approximately $24 million private placement.
- The financing covers 20,338,974 shares, with proceeds intended for working capital, research and development, and general corporate purposes.
- The company also highlighted early-stage neurotechnology research for sleep-related conditions, supporting continued speculative interest.
- The advance extends a sharp seven-session rally despite broader biotech weakness and a risk-off market backdrop.